Tumor Marker Testing Excellence
with TumorTrack Advance

Quicker, Smarter & Better test for treatment decision

What is TumorTrack Advance?

TumorTrack Advance is a next generation sequencing (NGS) assay consisting of DNA and RNA based testing which detects single nucleotide variants (SNVs), insertion-deletion mutations (InDels), copy number variants (CNVs), fusions, tumor mutation burden (TMB), microsatellite instability (MSI) and PD-L1 expression in multiple solid tumors.

tumor marker test

Coverage

cancer marker blood test

Coverage of Biomarkers

lung cancer

Lung Cancer

breast tumor test

Breast Cancer

ovarian cancer

Ovarian Cancer

prostate cancer

Prostate Cancer

gastrointestinal cancer

Gastrointestinal Stromal Tumor

thyroid cancer

Thyroid Cancer

colorectal cancer

Colorectal Cancer

melanoma cancer

Melanoma

bladder cancer

Bladder Cancer

uterine cancer

Uterine Cancer

pancreatic cancer

Pancreatic Cancer

hepatocellular cancer

Hepatocellular Carcinomas

sarcoma cancer

Sarcomas

thymus cancer

Thymus Cancer

glioma cancer

Glioma

Prevalence

cancer marker test
  • According to ICMR report the number of Indians suffering from cancer is projected to increase to 29.8 million in 2025 from 26.7 million in 2021
  • Males are at 9.81% risk to develop cancer before the age of 75 and females at 9.42%
  • The most common types of cancer in males include lip, oral cavity, lung, stomach, colorectal, and esophagus, while in females it includes breast, lip, oral cavity, cervix, lung, and gastric cancers (in descending order)

Why you need the test?

Single holistic test for the diagnosis, prognosis and to determine treatment options (Targeted Therapy & Immunotherapy)

tumor marker test cancer tumor markers blood test diagnostic test for cancer
cancer marker screening

Actionable/Potentially actionable variants identified in cancer patient samples from published data:

diagnostic test for cancer

Test Details

Test DetailsTest CodeSample TypeTAT
TumorTrack Advance (SNVs, InDels, CNVs, Fusions, TMB and MSI)MGM1785 +PD-L1 Expression by IHC*FFPE Tissue Block >10% Tumor content Histopathology Report21 Working Days
TumorTrack Plus (SNVs, InDels, CNVs, Fusions, TMB and MSI)MGM1785
TumorTrack Plus (SNVs, InDels, CNVs and Fusions)MGM1879
TumorTrack + MSIMGM1784
TumorTrack + TMBMGM1556
TumorTrack without FusionsMGM2559

Assay specifications

Cancer typeSpecimenFFPE block requirement*Tumor Purity MinimumLimit of detectionAverage depth of sequencingAnalytical sensitivityAnalytical specificity
All Solid Tumor TypesFFPE Tissue Block/Cytology Cell Block, Tissue in RNA later*Cross-sectional tumor area of 25mm2 containing at least 40 μm of tumor tissue>10% (as determined by Molecular Pathologist) 5% VAF for SV and InDels >10 Spanning Reads for Fusions >2.5-fold Change for CNV>250X99.15% (SNVs/InDels); 98% Fusions; ≥85-90% (CNVs) 99.9%

Why MedGenome?

  • Strict quality control measures at different stages of sample processing, data acquisition and analysis adhering to international clinical laboratory practice guidelines such as CAP, thus ensuring highly precise and accurate results
  • High throughput NGS data analysis, curation, and interpretation of the mutations and fusions are performed by well-trained clinical scientists/genome analysts and cancer genome experts
  • The report provides –
    → Clinically significant alterations and its interpretations
    → Their associations with drug efficacy
    → Recommended targeted therapies/possible mechanisms of resistance
    → Prognosis and available active clinical trials
  • Supporting medical evidence from large clinical studies that guide oncologists in making treatment decisions during the complete course of cancer management that includes diagnosis, targeted therapy, surveillance and relapse
  • Clinical reporting and interpretations are based on international guidelines such as ASCO, AMP, CAP, NCCN, and ESMO
  • The test is validated in-house and the mean sequencing depth of the panel is >/= 250x on 100+ clinical samples, reference standards, and cell lines
  • The sensitivity, specificity, and accuracy to detect SNVs, Short InDels, and fusions as mentioned below

Sample Type
Reference Standards (Horizon Diagnostics/Cell Lines/Clinical Samples)
Mutation TypeSensitivitySpecificityAccuracyLimit of detection
SNV/Short InDels (<10 bp)100%100%100%>= 5% for SNVs and >=10% of Short Indels
Fusion*95%100%100%NA (Qualitative)
Copy Number Variations**100%100%100%NA (Qualitative)

* Any gene fusion detected with a confidence of more than 10 spanning read support will be considered a true mutant

** Gene amplifications from NGS is based on prediction algorithms using bioinformatics approach. Any gene predicted to have a copy number >= 6 copies is considered as a true prediction for a probable gene amplification that needs to be confirmed using alternate testing platforms viz MLPA, FISH and other technologies. In-house clinical validation limits to CNV prediction for ERBB2 and MET Oncogene.

 

FAQs

SNVs and small INDELs detected by DNA Sequencing

AKT1, AKT2, AKT3, ALK, APC, AR, ARID1A, ATM, ATR, BAP1, BARD1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BRIP1, BTK, CARD11, CCND1, CCND2, CCNE1, CD79A, CD79B, CDH1, CDK12, CDK4, CDK6, CDKN2A, CEBPA, CHEK1, CHEK2, CREBBP, CSF1R, CTNNB1, DDR2, DNMT3A, EGFR, EP300, ERBB2, ERBB3, ERBB4, ERCC1, ERCC2, ERG, ESR1, EZH2, FBXW7, FGF3, FGF4, FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT3, FOXL2, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, INPP4B, JAK2, JAK3, KDR, KIT, KMT2A, KRAS, MAP2K1, MAP2K2, MCL1, MDM2, MDM4, MET, MLH1, MPL, MRE11, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL, MYCN, MYD88, NBN, NF1, NOTCH1, NOTCH2, NOTCH3, NPM1, NRAS, PALB2, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PIK3CG, PIK3R1, PMS2, PTCH1, PTEN, PTPN11, RAD51, RAD51C, RB1, RET, RICTOR, ROS1, SMAD4, SMARCB1, SMO, SRC, STK11, TERT, TET2, TP53, TSC1, TSC2, VHL

 

Gene translocations/fusions detected by RNA Sequencing

ABL1, AKT3, ALK, AR, AXL, BCL2, BCL6, BRAF, BRCA1, BRCA2, CCND1, CCND2, CDK4, CDKN2A, CSF1R, CTLA4, DUSP22, EGFR, EML4, ERBB2, ERG, ESR1, ETS1, ETV1, ETV4, ETV5, EWSR1, FGFR1, FGFR2, FGFR3, FGFR4, FLI1, FLT1, FLT3, FUS, HOXA1, HOXA10, HOXA11, HOXA13, HOXA2, HOXA3, HOXA4, HOXA5, HOXA6, HOXA7, HOXA9, IRF4, ITK, JAK2, KDR, KIF5B, KIT, KMT2A, LCK, LMO1, LMO2, LYL1, MDM2, MET, MLLT3, MSH2, MYB, MYBL1, MYC, NOTCH1, NOTCH2, NOTCH3, NRG1, NTRK1, NTRK2, NTRK3, PAX3, PAX7, PDGFRA, PDGFRB, PIK3CA, PPARG, RAF1, RELA, RET, ROS1, RPS5KB1, RPS6KB1, SS18, TCF3, TCL1A, TLX1, TLX3, TMPRSS2, TP53, TP63

 

ATK1, FGFR1, AR, FGFR2, BRCA1, PIK3CA, BRCA2, PTEN, ERBB2, PD-L1, ESR1, and PGR

 

BRCA1, BRCA2, KRAS, PDGFRA, FOXL2, TP53, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L

 

POLE, MLH1, MSH2, PMS2, MSH6, TP53, ERBB2, and ESR1

 

AKT1, MSH2, BRAF, MSH6, HRAS, NRAS, KRAS, PIK3CA, MET, PMS2, MLH1, PTEN, SMAD4, and
Her2 Amplification

 

ALK, BRAF, BRCA1, BRCA2, ERBB2, KRAS, NRG1, PALB2, ROS1

 

ATM, BRCA1, BRCA2, MLH1, MSH2, PMS2, MSH6, AR, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L

 

AKT1, ALK, BRAF, DDR2, EGFR, ERBB2, FGFR1, FGFR2, FGFR3, KRAS, MAP2K1, MET, NRAS, PIK3CA, PTEN, RET, TP53, PD-L1*, and Her2 Amplification

 

NTRK1, NTRK2, NTRK3, TMB, MSI, and PD-L1*
*Performed by IGC (SP263/SP142/22c3)
IHC – Immunohistochemistry

 

Brochures

Comprehensive Genomic Profiling TumorTrack

Download

Patient Stories

63-year-old Santosh Khurrana (name changed) felt the symptoms related to lung cancer

Free Genetic Counseling by MedGenome Genetic Experts

Please share your details with our genetic experts to answer your queries
Enquire Now Call Now

Test Menu

Genetic Counselling

Microsites

Collaterals

Contact Us